Business Context and Reporting Period
This Form 8-K filing by Collegium Pharmaceutical, Inc. (NASDAQ: COLL) reports a corporate governance event dated February 3, 2025. The Company, incorporated in Virginia, announced the expansion of its Board of Directors and the appointment of a new director.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the appointment of a new director and associated compensation arrangements.
Material Changes
- Board Expansion: The Board of Directors expanded from eight to nine members.
- New Appointment: Nancy Lurker was appointed as a director, effective February 4, 2025.
- Compensation Structure: Ms. Lurker will receive an annual cash retainer of $50,000 (prorated) and an initial grant of restricted stock units (RSUs) valued at $412,500.
Guidance, Outlook, and Management Commentary
The filing contains no financial guidance, operational outlook, or management commentary regarding business strategy. It notes that Ms. Lurker brings significant experience, having previously served as CEO of EyePoint Pharmaceuticals and PDI, Inc., and held senior roles at Novartis, Pharmacia, and Bristol-Myers Squibb. The Board determined Ms. Lurker is independent under Nasdaq listing rules.
Investor Verification Checklist
- Verify the vesting schedule for the $412,500 RSU grant (vests on the first anniversary of the grant date).
- Confirm the total number of directors on the Board is now nine.
- Review the Company's non-employee director compensation policy to understand the full annual equity award structure.
- Check for any related party transactions involving Ms. Lurker (none disclosed in this filing).